Virtual Library
Start Your Search
Linda W Martin
Author of
-
+
ES03 - Understanding and Treating Oligometastatic Diseases (ID 161)
- Event: WCLC 2020
- Type: Educational Session
- Track: Locoregional and Oligometastatic Disease
- Presentations: 1
- Moderators:
- Coordinates: 1/29/2021, 10:30 - 11:30, Scientific Program Auditorium
-
+
ES03.01 - Chair (ID 3975)
10:30 - 11:30 | Presenting Author(s): Linda W Martin
- Abstract
Abstract not provided
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy (ID 256)
- Event: WCLC 2020
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P79.06 - CHIO3: ChEmotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer (AFT-46) (ID 1916)
00:00 - 00:00 | Presenting Author(s): Linda W Martin
- Abstract
Introduction
Stage IIIA/B (T1-3, N2) non-small cell lung cancer (NSCLC) continues to be a clinical challenge with 5‑year survival of 15%-40%. Both local and distant recurrence plagues this population. Optimal management remains uncertain. Intergroup 0139 showed a doubling of survival in the subset of patients treated with chemoradiotherapy (CRT) followed by lobectomy versus CRT alone (36% vs. 18%, 5‑year survival, p=0.002). The addition of immunotherapy to CRT has shown promising results in the PACIFIC trial, in a nonoperative stage III population (HR for overall survival=0.69; 95% CI 0.55-0.86 compared to CRT only). Interest has grown in combining four modes of therapy in a manner that minimizes toxicity; this has potential to transform the historically poor outcomes for operable stage III NSCLC.
The population targeted in this trial is operable stage IIIA/B NSCLC, with histologically documented N2 disease. We seek to assess the feasibility and clinical impact of combined platinum doublet chemotherapy with 1125 mg durvalumab for operable stage III NSCLC as neoadjuvant therapy prior to anatomic resection, followed by postoperative radiation to 50-54 Gy, and subsequently durvalumab 1500 mg IV q 4 weeks for 1 year (Figure).
Methods
Patients with resectable Stage IIIA/B (T1-3 N2) NSCLC with biopsy proven N2 nodal involvement, performance status 0-1, adequate organ function and no contraindication for immunotherapy are potentially eligible. Target enrollment is 55 patients, anticipating 42 will undergo resection. Our hypothesis is that N2 nodal clearance (N2NC) will be higher (50% or greater) for neoadjuvant platinum doublet chemotherapy with durvalumab than historically observed (30% on average) for platinum doublet chemotherapy alone. The N2NC rate is the primary endpoint. In addition there will be a number of secondary endpoints including assessment of pathologic response, safety and tolerability, and overall survival.
Support: AFT, Astra-Zeneca; https://acknowledgments.alliancefound.org. ClinicalTrials.gov Identifier: NCT04062708